๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR ยท Real-Time Price ยท USD
8.87
-0.28 (-3.06%)
At close: Nov 19, 2026, 4:00 PM EST
8.84
-0.03 (-0.34%)
Pre-market: Nov 20, 2026, 5:06 AM EST

Vir Biotechnology Earnings Call Transcripts

Fiscal Year 2026

  • ECLIPSE 1 showed nearly 80% undetectable viral RNA at week 48, with HDV results expected in Q1 2027 and filing planned for mid-2027. Oncology pivotal trials are targeted for 2027, supported by PRO-XTEN collaborations and cash runway into 2029.

  • Status update

    ECLIPSE 1 met its endpoints, with 79% reaching undetectable HDV RNA at week 48 and favorable tolerability. SOLSTICE showed sustained week 96 suppression and early off-treatment responses; ECLIPSE 2/3 data are expected in Q1 2027, ahead of a planned mid-2027 FDA filing.

  • Phase III HDV readouts are approaching, while VIR-5500 advances toward pivotal development. The Gilead deal adds $90M upfront and extends projected cash runway into H2 2028.

  • Strong Q2 2026 results driven by major collaboration revenue and robust clinical progress in hepatitis delta and oncology. Cash position improved to $1.01 billion, supporting a runway into 2028. Key clinical milestones are on track, with best-in-class efficacy data and commercial readiness advancing.

  • AGM 2026

    The meeting introduced board and executive changes, presented three shareholder proposals, and confirmed the election of directors, approval of executive compensation, and auditor ratification. Voting outcomes will be formally reported to the SEC.

  • Multiple value creation paths are advancing, including a near-term Delta Program, a differentiated oncology platform, and a robust HDV regimen outperforming competitors. Strategic partnerships and a strong cash position support parallel development and targeted commercial build-out.

  • Major advances in oncology and hepatitis delta programs, highlighted by a $1.7B Astellas collaboration and strong phase II data for tobevibart plus elebsiran. Cash runway extends into 2H 2028, supporting multiple milestones and disciplined capital allocation.

  • The company is advancing a robust immuno-oncology and infectious disease pipeline, highlighted by strong efficacy and safety data for its masked T-cell engager in prostate cancer and a promising dual regimen for hepatitis delta. Strategic partnerships and financing have extended cash runway to 2028.

  • VIR-5500 showed strong efficacy and safety in late-stage prostate cancer, enabling expansion and pivotal trials next year. The Astellas partnership accelerates development with significant financial terms and joint governance. Pipeline and HDV programs advance, with a robust cash position supporting growth.

  • The presentation detailed progress on a transformative pipeline targeting hepatitis Delta and solid tumors, with lead assets showing strong efficacy and safety. Strategic partnerships and a robust discovery engine support long-term growth, with key data readouts and commercial milestones expected through 2027.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023